Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

NYBC receives FDA approval for HEMACORD HPC-C cell therapy

The U.S. Food and Drug Administration today approved HEMACORD, the first licensed hematopoietic progenitor cells-cord (HPC-C) cell therapy.

10 Nov 2011

Tregs expansion can help prevent graft-versus-host disease

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD.

1 Nov 2011

Biomarker can help identify GVHD in cancer patients after hematopoietic stem cell transplant

A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.

22 Oct 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

Researchers use ultrasound to improve quality of blood stem cell transplant

Transplantation of haematopoietic stem cells is an effective treatment for patients with malignant blood diseases. The composition and quality of the transplanted cells are crucial to the outcome. Researchers from Lund University, Sweden, have now developed a method to improve the quality of the transplanted cells using ultrasound for cell separation.

7 Sep 2011

NCRM at Case Western Reserve to host stem cell conference in Cleveland

The National Center for Regenerative Medicine (NCRM) at Case Western Reserve University is proud to present "MSC 2011: Innovations in Cell-Based Regenerative Therapies," a three-day forum to highlight transformative breakthroughs in the area of adult stem cell medicine with a focus on how this research is being applied in patient care settings through innovative clinical trials.

18 Aug 2011

Soligenix second quarter revenues decrease to $406,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2011.

12 Aug 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.

19 May 2011

Researchers develop new gene therapy technique for CGD treatment

Researchers have developed an effective technique that uses gene therapy on stem cells to correct chronic granulomatous disease in cell culture, which could eventually serve as a treatment for this rare, inherited immune disorder, according to a study published in Blood, the Journal of the American Society of Hematology.

29 Apr 2011

Cenovus donates $1.3 million to Alberta Children's Hospital to combat childhood cancer

Cenovus Energy Inc. is proud to announce that the company has committed $1.3 million to the Alberta Children's Hospital Foundation to help experts at the Alberta Children's Hospital in the fight against childhood cancer.

8 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.

25 Mar 2011

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Life Technologies Corporation today announced it has received FDA 510(k) clearance for StemPro MSC SFM – a first for this next-generation stem cell culture medium that is now cleared as a medical device and satisfies a crucial requirement for researchers involved in clinical trials in the United States.

14 Mar 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

For blood cancer patients at high risk of relapse, hematopoietic stem cell transplantation (HSCT), the transplantation of blood-forming stem cells, is one of best options for treatment and a potential cure. Unfortunately, the most common complication of HSCT is graft-versus-host disease (GVHD), a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells recognize the recipient's own cells as foreign and react by attacking the cells in the patient's body.

4 Feb 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Soligenix third quarter revenues increase to $5,796,000

NYBC receives FDA approval for HEMACORD HPC-C cell therapy

Tregs expansion can help prevent graft-versus-host disease

Biomarker can help identify GVHD in cancer patients after hematopoietic stem cell transplant

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Researchers use ultrasound to improve quality of blood stem cell transplant

NCRM at Case Western Reserve to host stem cell conference in Cleveland

Soligenix second quarter revenues decrease to $406,000

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Half-matched transplants widen donor pool for leukemia and lymphoma

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

Researchers develop new gene therapy technique for CGD treatment

Cenovus donates $1.3 million to Alberta Children's Hospital to combat childhood cancer

NeoStem revenues increase 13% for the year ended December 31, 2010

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in